遗传性抗凝血酶缺乏症中新发现SERPINC1变异:首个致病性深内含子变异
本研究纳入10个抗凝血酶缺乏症家系共42人,采用基因组与转录组学方法覆盖SERPINC1全区域,鉴定出3个新变异及一个外显子6缺失;其中c.42-209T>G为首个经功能验证的致病性深内含子变异,通过异常剪接降低转录水平。
要点
- 在先前未检出SERPINC1变异的家系中,覆盖全区域可发现新变异。
- c.42-209T>G为首个致病的深内含子变异,经异常剪接机制验证。
- 所有新变异与疾病共分离,支持其致病性。
核心结论
- 报告了数个新的SERPINC1变异,其中c.42-209T>G是首个通过异常剪接导致抗凝血酶缺乏症的致病性深内含子变异。
研究设计与样本
- 单中心队列研究,纳入10个抗凝血酶缺乏症家系共42人,这些家系先前未鉴定出SERPINC1变异。
- 采用多种基因组和转录组学方法鉴定新变异,并按SERPINC1特异性ACMG标准分类。
主要发现
- 鉴定出3个新SERPINC1变异:c.42-209T>G、c.1153+429C>T和c.916T>G,另发现一个外显子6缺失(新颖性不确定)。
- 所有变异完美共分离;c.42-209T>G按ACMG标准为意义未明变异,经功能测试确认致病。
- 预测工具提示c.42-208位引入 acceptor 剪接位点,导致包含假外显子的转录本,引入提前终止密码子。
- 通过qPCR和Sanger测序cDNA(来自基因组编辑的HepG2细胞RNA)证实异常剪接,且c.42-209T>G降低SERPINC1转录水平。
关键数值与推荐
- 按SERPINC1特异性ACMG标准分类变异;c.42-209T>G为唯一意义未明变异,经功能验证后判定致病。
临床怎么用
- 对常规检测未发现SERPINC1变异的抗凝血酶缺乏症家系,建议覆盖全区域包括深内含子进行检测。
- 对于疑似深内含子变异,可结合转录组分析和功能实验(如剪接验证)明确致病性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antithrombin deficiency is a rare hereditary predisposition to venous thromboembolism caused by variants in the SERPINC1 gene. In up to 20% of cases, no explanatory variant is identified. OBJECTIVES: This study uncovered novel variants by covering the full SERPINC1 region. METHODS: In this single-center cohort study, we included antithrombin-deficient families in which no SERPINC1 variant had been previously identified. We used multiple genomic and transcriptomic approaches to identify novel variants and assess their pathogenicity. Variants were classified according to SERPINC1-specific American College of Medical Genetics and Genomics criteria. RESULTS: We included 10 families with 42 individuals and identified 3 novel SERPINC1 (NM_000488.4) variants: c.42-209T>G, c.1153+429C>T, and c.916T>G. In addition, we identified an exon 6 deletion of uncertain novelty. All variants cosegregated perfectly. Despite being highly suspect, c.42-209T>G was the only variant of uncertain significance according to American College of Medical Genetics and Genomics criteria, which prompted us to perform functional testing. Prediction tools suggested the introduction of an acceptor splice site at c.42-208, resulting in the inclusion of a pseudoexon with premature stopcodon. We confirmed this aberrant splicing prediction by quantitative polymerase chain reaction and Sanger sequencing of cDNA synthesized from RNA isolated from genomic-edited HepG2 cells. c.42-209T>G leads to a reduction of SERPINC1 transcript levels. CONCLUSION: We report several novel SERPINC1 variants, one of which is the first pathogenic deep-intronic variant causing antithrombin deficiency through aberrant splicing. This finding improves our understanding of the genetic etiology and clinical practice for antithrombin deficiency. In all tested families registered with our institution, an explanatory SERPINC1 variant has now been identified.
引用
- Remmelzwaal PC, Mulder R, de Boer-Bergsma JJ, et al. Novel SERPINC1 variants in hereditary antithrombin deficiency: first pathogenic deep-intronic variant, revealed by multiple genomic and transcriptomic approaches. J Thromb Haemost. 2026. PMID: 42202885. doi:10.1016/j.jtha.2026.05.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。